WALTHAM, MA -- September 26, 2007 -- PerkinElmer Life and Analytical Sciences, a global leader in application-focused measurement and analysis solutions, today announced the introduction of the Clarus® 400 gas chromatograph (GC), designed to meet the needs of industrial/analytical laboratories in price-sensitive environments and academic laboratories globally.

“Increasingly, we are tailoring our offerings to meet the skill level, analytical and productivity demands of the user. We developed the Clarus 400 GC in response to the strong demand for reliable, world-class GC technology in budget-conscious laboratories without sacrificing performance,” said Eric Ziegler, Vice President of Chromatography for PerkinElmer Life and Analytical Sciences. “For example, the Clarus 400 GC’s single-channel and dual-channel capability with choice of injectors and detectors offers the flexibility and performance to meet diverse applications needs.”

The Clarus 400 GC offers an optional autosampler for increased productivity and has a number of features to support laboratories in global markets including a choice of keypad user interfaces in five languages. It is designed for an easy installation supported by localized documentation. Also, as with all other GCs in the Clarus family, the Clarus 400 GC can be coupled with PerkinElmer’s TurboMatrix™ Headspace Samplers and Thermal Desorbers for added application capabilities.

The Clarus 400 GC is an integral part of PerkinElmer’s Clarus family of GC instrumentation for customers in the environmental, food and beverage, forensics, petrochemical, materials testing and academic markets. In addition, PerkinElmer is the only gas chromatography supplier who develops, manufactures, supports and services every product it offers to provide a truly integrated system. This means one expert supplier – with best-in-class instruments and a world-class service and support organization – can address all of your applications and troubleshooting needs, from sample handling to data handling.

For more information, visit www.perkinelmer.com/Clarus400GC. 

The Clarus 400 GC will be featured at the following upcoming conferences: Analitica Latin America (Sept. 26-28 – Sao Paulo, Brazil), Beijing Conference and Exhibition on Instrumental Analysis (Oct. 18-21 – Beijing, China), Analytica-Anacon (Oct. 31-Nov. 2 – Hyderabad, India).

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.